Johnson & Johnson
Health
Performance
2.2
Risk
Sell
Buy
Curious about the Scores? Learn more.

Johnson & Johnson stock rating and score history

All changes in ratings, performance and outlook tracked over time.

19.12.2025
Slowing down. Might be a breather – or a shift.
04.12.2025
Still low-risk, but small tremors appearing.
12.11.2025
From weak to decent. The first signs are finally showing.
20.08.2025
Health’s picking up. Numbers look cleaner, cash flow tighter.

Johnson & Johnson stock price, chart patterns and momentum

Recent price movements, trend behaviour and momentum signals based on real-time market data.

What does Johnson & Johnson do? Business model and key facts

Get the full picture of Johnson & Johnson: what it builds, where it operates, and how it makes money.

Johnson & Johnson Profile

Sector: Healthcare

Industry: Drug Manufacturers - General

Employees (FY): 138100

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

shop
Company facts
Joaquin Duato
CEO
138100
Employees worldwide
shop
Performance
51.46%
Last 12 months
36.97%
Last 5 years
shop
Growth
$88,82B
Revenue year
$14,07B
Net income
shop
Valuation
$529,01B
Market Cap
24.53
Price/Earnings Ratio

Stocks related to Johnson & Johnson

Selected based on industry alignment and relative market positioning.

LLY
Low-poly 3D Eli Lilly (LLY) stock icon with a stylized pill capsule, symbolizing healthcare and biotech.
1,032.97
-3.76%
4.4
Sell
Buy
Eli Lilly and Company
ABBV
Low-poly 3D AbbVie (ABBV) stock icon with a stylized molecule, symbolizing healthcare and biotech.
216.75
-2.32%
2.7
Sell
Buy
AbbVie Inc.
AZN
Low-poly 3D AstraZeneca (AZN) stock icon with a stylized molecule, symbolizing healthcare and biotech.
93.99
-2.44%
2.4
Sell
Buy
AstraZeneca PLC
NVS
Low-poly 3D Novartis (NVS) stock icon with a stylized pill capsule, symbolizing healthcare and biotech.
143.15
-2.06%
1.7
Sell
Buy
Novartis AG
MRK
Low-poly 3D Merck (MRK) stock icon with a stylized molecule, symbolizing healthcare and biotech.
110.96
-0.05%
3.2
Sell
Buy
Merck & Co., Inc.

Johnson & Johnson fundamentals and technical analysis

Financial fundamentals and technicals signals combined to access stability, momentum and market direction.